Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2020 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13

TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
June 22, 2020 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting

TEL AVIV, Israel, June 22, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today presented a late-breaking study showing that its proprietary MOSPD2 bi-specific antibody candidates induced...
June 04, 2020 07:00 ET | Source: VBL Therapeutics

VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress

TEL AVIV, Israel, June 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced new data implicating the potential of its proprietary anti-MOSPD2 antibodies for...
June 01, 2020 07:00 ET | Source: VBL Therapeutics

VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate

OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10%...
May 18, 2020 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting

TEL AVIV, Israel, May 18, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that new data suggesting the potential of its proprietary bi-specific antibodies for...
May 14, 2020 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate Update

TEL AVIV, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update. ...
May 13, 2020 18:23 ET | Source: VBL Therapeutics

VBL Therapeutics Closes $8.1 Million Registered Direct Offering to Key Current Shareholders Priced At-the-Market under Nasdaq Rules

TEL AVIV, Israel, May 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced offering of 5,142,857 ordinary shares of the Company,...
May 12, 2020 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Closes $10.0 Million Registered Direct Offering and Announces $8.1 Million Registered Direct Offering to Key Current Shareholders, Each Priced At-the-Market under Nasdaq Rules

TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary...
May 07, 2020 09:22 ET | Source: VBL Therapeutics

VBL Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for the...
May 06, 2020 07:00 ET | Source: VBL Therapeutics

VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW

Study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction Data demonstrate the potential of VBL's proprietary MOSPD2 mAbs for chronic inflammatory...